Early research (Phase 1)Looking for participantsNCT07554222
What this trial is testing
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Who this might be right for
HealthyActive Non-segmental VitiligoSevere Alopecia Areata
Innovent Biologics (Suzhou) Co. Ltd. 160